Dyne therapeutics competitors

Author: bjcv

August undefined, 2024

WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … WebDyne Therapeutics has 5 employees at their 1 location and $165 m in total funding,. See insights on Dyne Therapeutics including office locations, competitors, revenue, …

Dyne Therapeutics - Overview, News & Competitors

WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. WebApr 7, 2024 · Summary Competitors Valuation Apr 7, 2024. ... Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is ... philips sonicare hx6970

Dyne Therapeutics, Inc. (DYN) Key Stats Comparison

WebApr 4, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they … WebMay 16, 2024 · About Dyne Therapeutics. Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... Sector and Competitors. 1st jan. Capi. (M$) DYNE THERAPEUTICS, INC.-26.40%: 497: MODERNA, INC.-13.39%: 59 996: … WebDyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for … philips sonicare hx 8230

DYN - Dyne Therapeutics Inc Stock quote - CNNMoney.com

WebDyne Therapeutics Inc 's competitive profile, comparisons of quarterly results to its competitors, by sales, income, profitability, market share by products and services - … WebDec 30, 2024 · Peers & Competitors. Follow $11.59 0.19 (+1.67%) 3:59 PM 12/30/22. ... Dyne Therapeutics, Inc. (DYN) key stats comparison: compare with other stocks by … trx wrappedWebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … trxx mining

"WebNov 3, 2024 · A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In June 2024, Dyne … " - Dyne therapeutics competitors

Dyne therapeutics competitors

Dyne Therapeutics Reports Third Quarter 2024 Financial Results …

WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT evaluated monthly repeat doses of DYNE-101 ... WebApr 4, 2024 · Dyne Therapeutics currently has a consensus target price of $25.83, suggesting a potential upside of 133.79%. Given Dyne Therapeutics’ higher possible upside, equities analysts plainly believe ...

Did you know?

WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebAug 1, 2024 · Dyne Therapeutics: ClinicalTrials.gov Identifier: NCT05481879 Other Study ID Numbers: DYNE101-DM1-201 2024-000889-18 ( EudraCT Number ) First Posted: August 1, 2024 Key Record Dates: Last Update Posted: April 7, 2024 Last Verified: April 2024 Individual Participant Data (IPD) Sharing Statement: ...

WebDyne Therapeutics’s Profile, Revenue and Employees. Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Dyne Therapeutics’s primary competitors include Avidity Biosciences, Sarepta Therapeutics, Neurana and 6 more. WebMar 23, 2024 · Dyne Therapeutics sets IPO terms, to offer 10.3 million shares priced at $16 to $18 each. Sep. 10, 2024 at 7:12 a.m. ET by Ciara Linnane.

WebFind company research, competitor information, contact details & financial data for Dyne Therapeutics, Inc. of Waltham, MA. Get the latest business insights from Dun & … WebDyne Therapeutics is a public company that has been in the industry for 6 years. The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. The position of the President & CEO is occupied by Joshua Brumm. Its headquarters is located at Waltham, Massachusetts, USA. The number of employees ranges from 25 to …

WebDyne Therapeutics closed its last funding round on Jan 21, 2024 from a Post-IPO Equity round. Who are Dyne Therapeutics 's competitors? Alternatives and possible …

WebFind contact information for Dyne Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Dyne Therapeutics's … trxxs-winkel lommel traxxasWebThe Competitors page allows you to view information for other symbols found in the same sector. In the table, you'll find all the components (individual stock symbols) found in that … trxxshedWebOct 2, 2024 · Dyne Therapeutics Competitors. There are no companies similar to Dyne Therapeutics Dyne Therapeutics Related Companies. ... No industry vertical has been recorded for Dyne Therapeutics View All. Dyne Therapeutics Recommended Market Profiles (6) Telemedicine. 10,000 or More employees. 19 companies. philips sonicare hx9023 65WebFind contact information for Dyne Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Dyne Therapeutics's email format. ... Dyne Therapeutics Top Competitors. Company Employees Revenue Top technologies; Akouos. 57: $19.2 M: Generation Bio. 106: $18.5 M: Leap Therapeutics. … philips sonicare hx9331 diamondclean electricWebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... trxye downloadWebSep 6, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … trxxmount3 trxx700xx kn oil filter